Recursion Presents Phase 2 REC-4881 Data Showing Polyp Reductions in FAP
Recursion Pharmaceuticals said Phase 2 REC-4881 data presented at CGA-IGC showed deep, durable polyp burden reductions in FAP.
Recursion Pharmaceuticals said Phase 2 REC-4881 data presented at CGA-IGC showed deep, durable polyp burden reductions in FAP.